SS
ADCT icon

SBI Securities’s ADC Therapeutics ADCT Stock Holding History

SBI Securities’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-222
Closed -$784 – 4014
2025
Q4 		$784 Sell
222
-4
-2% -$16 ﹤0.01% 2726
2025
Q3 		$904 Buy
226
+4
+2% +$13 ﹤0.01% 2736
2025
Q2 		$595 Hold
222
– – ﹤0.01% 2900
2025
Q1 		$313 Sell
222
-10
-4% -$17 ﹤0.01% 3049
2024
Q4 		$462 Buy
+232
New +$607 ﹤0.01% 2918

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SBI Securities's ADCT Position: Q1 2026 in Review

SBI Securities sold out of ADC Therapeutics (ADCT) in Q1 2026, closing a stake of 222 shares — an estimated $784 sold.

SBI Securities first reported a position in ADCT in Q4 2024 and held it in 5 quarters. The position peaked at $904 in Q3 2025. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • SBI Securities reported no remaining ADC Therapeutics position as of Q1 2026 after selling out during the quarter.
  • SBI Securities sold 222 ADC Therapeutics shares in Q1 2026, an estimated $784.
  • SBI Securities first reported a position in ADC Therapeutics in Q4 2024 and held it in 5 quarters.
  • SBI Securities's ADC Therapeutics position peaked at $904 in Q3 2025.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on SBI Securities's 13F filing for Q1 2026, filed 28 Apr 2026.